Business
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia
LA JOLLA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the
About this update from Medicinova, Inc.
[{"type":"text","content":"LA JOLLA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional analyses of MediciNova’s completed clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis), which was conducted at Carolinas HealthCare System’s Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute, will be presented on December 5, 2019 at 10:30 am local time at the 30th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) in Perth, Australia. \n Highlights of the presentation, entitled \"Interaction (nonuniformity) of ALS Progression and the Efficacy of MN‑166 (ibudilast)”, which will be presented by Kazuko Matsuda, M.D. Ph.D. M.P.H., Chief Medical Officer of MediciNova, Inc., include the following: We evaluated the potential background factors of patients’ characteristics that could reasonably predict both ALS disease progression and treatment efficacy. These factors included gender, age, race, site of onset (upper limb, lower limb, bulbar onset), UMN (upper motor neuron) / LMN (lower motor neuron) symptom involvement, and ALS history (i.e. days from first onset of symptom to trial enrollment).Regression Tree Analysis and Stepwise Regression Analysis were performed to determine which potential factors have an impact on the treatment effect of MN-166 as assessed by the ALSFRS-R score.The regression analyses determined that ALS history was a statistically significant factor affecting treatment effect (p=0.015).Correlational Analysis was conducted to analyze the correlation between (1) ALS history and baseline ALSFRS-R score, and (2) ALS history and disease progression, measured as change in ALSFRS-R score from baseline to end of treatment.A significant negative correlation (-0.72, p","length":2427,"tagName":"div"}]